AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 221 min read$SOPH

CARDOZA GEORGE sold $6K of SOPH

CARDOZA GEORGE (Chief Financial Officer) sold 774 shares of SOPHiA GENETICS SA (SOPH) at $8.33 on 2026-09-21 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CARDOZA GEORGE
Published Sep 22, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
high confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The disclosed sale is a routine liquidity event with negligible impact on SOPHiA's share price.

02

Market read

Routine insider sale; low relevance for traders.

03

What to watch

Potential upcoming corporate events (e.g., earnings) could make the sale more relevant if timed with other news.

Relevance 2/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions; routine sales under a 10b5‑1 plan are common and usually not market‑moving.

Company-level read

Ticker impact

$SOPHNeutralHigh confidence
Context

CFO Cardoza George sold 774 shares for $6,447 via a 10b5‑1 plan, reducing his stake to 308,318 shares.

Expected impact

No material price movement expected.

Evidence & confidence

The transaction size is small relative to total holdings and typical for routine 10b5‑1 sales.

Market effects

Sector

None; SOPHiA operates in genomics data analytics, but the sale is too small to affect sector sentiment.

Regional

Limited to Swiss/US biotech investors.

Global

Low

Counterpoint

What could challenge this read

If the CFO were offloading shares aggressively, it could signal concerns, but the 10b5‑1 plan suggests pre‑scheduled execution.

Key entities

  • Company
    SOPHiA GENETICS SA

    Swiss genomics data company listed on NASDAQ under SOPH.

  • Executive
    Cardoza George

    Chief Financial Officer of SOPHiA GENETICS SA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SOPH insider trading history →

Related articles

AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min
AUG 4
$SOPHHighAI 9/10

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

prnewswire.com6 min
AUG 4
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q2 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30,

SEC EDGAR 6-K2 min
AUG 4
$SOPHMed

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

finanznachrichten.de4 min